We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
-6.45%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$112M
AUM Growth
-$20.6M
Cap. Flow
+$957K
Cap. Flow %
0.85%
Top 10 Hldgs %
39.2%
Holding
84
New
25
Increased
14
Reduced
14
Closed
25

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$4.87M
2
GERN icon
Geron
GERN
+$4.03M
3
VRDN icon
Viridian Therapeutics
VRDN
+$3.7M
4
DYN icon
Dyne Therapeutics
DYN
+$3.7M
5
RGNX icon
Regenxbio
RGNX
+$3.01M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$4.58M
2
RLAY icon
Relay Therapeutics
RLAY
+$4.46M
3
APLS
Apellis Pharmaceuticals
APLS
+$3.81M
4
BMY icon
Bristol-Myers Squibb
BMY
+$3.69M
5
BSX icon
Boston Scientific
BSX
+$3.62M

Sector Composition

Rank Sector Weight
1 Healthcare 97.89%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$16.5B
$5.72M 5.09%
165,496
-81,204
-33% -$2.74M
GH icon
2
Guardant Health
GH
$19.5B
$5.42M 4.82%
127,182
-20,618
-14% -$890K
GERN icon
3
Geron
GERN
$911M
$5.11M 4.54%
3,215,457
+1,654,305
+106% +$4.03M
AZN icon
4
AstraZeneca
AZN
$263B
$4.73M 4.2%
+16,267
New +$2.35M
CYTK icon
5
Cytokinetics
CYTK
$11B
$4.16M 3.7%
103,483
+37,600
+57% +$1.73M
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.84B
$4.14M 3.68%
337,198
+18,298
+6% +$258K
IONS icon
7
Ionis Pharmaceuticals
IONS
$9.35B
$4.09M 3.64%
135,616
+74,249
+121% +$2.43M
LLY icon
8
Eli Lilly
LLY
$1.07T
$3.86M 3.43%
4,673
-3,574
-43% -$2.97M
COGT icon
9
Cogent Biosciences
COGT
$6.79B
$3.72M 3.31%
+621,678
New +$4.87M
ISRG icon
10
Intuitive Surgical
ISRG
$121B
$3.15M 2.8%
6,358
-1,069
-14% -$591K
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
$3.1M 2.76%
43,441
-33,844
-44% -$1.65M
AKRO
12
DELISTED
Akero Therapeutics
AKRO
$3.09M 2.75%
76,379
+7,771
+11% +$329K
IRON icon
13
Disc Medicine
IRON
$2.83B
$3.06M 2.72%
61,656
-7,416
-11% -$412K
VRDN icon
14
Viridian Therapeutics
VRDN
$2.13B
$2.93M 2.6%
+217,294
New +$3.7M
RGNX icon
15
Regenxbio
RGNX
$623M
$2.9M 2.58%
+405,281
New +$3.01M
REPL icon
16
Replimune Group
REPL
$814M
$2.87M 2.56%
294,846
+240,108
+439% +$2.97M
SRRK icon
17
Scholar Rock
SRRK
$5.71B
$2.71M 2.41%
84,339
+6,900
+9% +$265K
DYN icon
18
Dyne Therapeutics
DYN
$4.04B
$2.7M 2.4%
+258,391
New +$3.7M
NTRA icon
19
Natera
NTRA
$37.5B
$2.64M 2.34%
18,650
-3,800
-17% -$611K
ETNB
20
DELISTED
89bio
ETNB
$2.57M 2.29%
353,882
+128,559
+57% +$1.12M
PEN icon
21
Penumbra
PEN
$12.5B
$2.41M 2.14%
9,000
– –
SVRA icon
22
Savara
SVRA
$1.13B
$2.32M 2.06%
836,397
+136,699
+20% +$377K
ANAB icon
23
AnaptysBio
ANAB
$1.6B
$2.17M 1.93%
+116,623
New +$1.95M
TVTX icon
24
Travere Therapeutics
TVTX
$5.33B
$2.11M 1.88%
+118,017
New +$2.4M
CNTA
25
DELISTED
Centessa Pharmaceuticals
CNTA
$2.05M 1.82%
142,744
+5,028
+4% +$82.3K
1
2 3 4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
MUAMU
Mitsubishi UFJ Asset Management (UK) London, United Kingdom $193M AUM 37.43% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
CWRP
Cassady Wealth & Retirement Planning Henderson, Nevada $193M AUM
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return

Exome Asset Management's Q1 2025 Portfolio in Review

As of Q1 2025, Exome Asset Management held 84 positions worth $112M, down 15% from $133M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Exome Asset Management's Q1 2025 filing shows 25 new, 14 increased, 14 reduced and 25 closed positions. Its largest new stake was Cogent Biosciences: 621,678 shares worth $3.72M. The largest sale was Humana, an estimated $4.58M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials.

  • Exome Asset Management's largest Q1 2025 buy was Cogent Biosciences: 621,678 shares worth $3.72M.
  • Exome Asset Management added most to Geron in Q1 2025, an estimated $4.03M increase.
  • Exome Asset Management's biggest Q1 2025 reduction was Eli Lilly, cutting an estimated $2.97M.
  • Exome Asset Management fully exited Humana in Q1 2025, selling an estimated $4.58M.
  • Exome Asset Management's ten largest holdings make up 39% of its $112M portfolio in Q1 2025.
  • Exome Asset Management opened 25 new positions and closed 25 in Q1 2025.
  • Exome Asset Management's portfolio value fell 15% quarter-over-quarter to $112M.

Based on Exome Asset Management's 13F filing for Q1 2025, filed 15 May 2025.